Amphastar Pharmaceuticals(AMPH)
Search documents
Amphastar Pharmaceuticals(AMPH) - 2021 Q1 - Earnings Call Transcript
2021-05-09 08:48
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2021 Earnings Conference Call May 6, 2021 5:00 PM ET Company Participants Dan Dischner - Vice President, Corporate Communications Bill Peters - Chief Financial Officer Tony Marrs - Senior Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Evan Hua - BMO Capital Markets Lucas Lee - Raymond James David Amsellem - Piper Sandler David Steinberg - Jefferies Tim Chiang - Northland Securities Serge Belanger - Needham & Company O ...
Amphastar Pharmaceuticals(AMPH) - 2020 Q4 - Earnings Call Transcript
2021-03-16 00:11
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2020 Results Conference Call March 15, 2021 5:00 PM ET Company Participants Dan Dischner - Vice President of Corporate Communications Bill Peters - Chief Financial Officer, Treasurer, and Senior Vice President of Finance Conference Call Participants Timothy Chiang - Northland Securities Gary Nachman - BMO Capital David Amsellem - Piper Sandler Elliot Wilbur - Raymond James David Steinberg - Jefferies Serge Belanger - Needham & Co Operator Greetings, and wel ...
Amphastar Pharmaceuticals(AMPH) - 2020 Q3 - Earnings Call Transcript
2020-11-09 03:49
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2020 Earnings Conference Call November 6, 2020 12:00 PM ET Company Participants Dan Dischner - Vice President of Human Resources & Corporate Communications Bill Peters - Chief Financial Officer Tony Marrs - Senior Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jacob Hughes - Wells Fargo Securities Tim Chiang - Northland Capital Markets David Amsellem - Piper Sandler Elliot Wilbur - Raymond James Serge Belanger - Needh ...
Amphastar Pharmaceuticals(AMPH) - 2020 Q3 - Quarterly Report
2020-11-06 21:11
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |------------------------------------------------------------------------------------------------ ...